Ophthalmologists from Mount Sinai to present research at the 56th Annual Retinal Society Scientific Meeting

(Image Credit: ©f11photo - Adobe.Stock.com)

At the Retinal Society’s 56th Annual Scientific Meeting, ophthalmologists from New York Eye and Ear Infirmary of Mount Sinai will present new research. The meeting will be held in New York City from October 11 through October 14, 2023. According to the press release¹, the following presentations will be among those given at the meeting.

• On October 12, 2023, R. Theodore Smith, MD, PhD, and Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai will give a presentation titled, “Inadequate Ophthalmic Perfusion and Subretinal Drusenoid Deposits: Proof of Principle”. In this presentation, he will share the methods and results on the study which evaluated ischemic stroke subjects for SDDs to determine if ocular hypoperfusion from internal carotid artery (ICA) stenosis is associated with ipsilateral SDDs.
  
• On October 13, 2023, Avnish Deobhakta, MD, Assistant Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai will have poster called, “Evaporative Heavy Liquids for Retinal Tamponade”. The purpose of this research was to identify a set of non-toxic optically clear canonical heavy liquids for retinal tamponade that can evaporate within the vitreous cavity under normal biological conditions.
  
• Nilesh Raval, MD, Ophthalmology Fellow at New York Eye and Ear Infirmary of Mount Sinai, will have a poster as part of the afternoon poster session titled, “A Modified Endolaser Instrument for Chandelier Scleral Buckles,” which will provide report on a novel modification of an illuminated endolaser probe facilitating safe endophotocoagulation during chandelier-assisted scleral buckle surgery. 
  
• Richard Rosen, MD, FACS, FASRS, Chief of the Retina Service for the Mount Sinai Health System will also give a talk entitled, “Mitochondrial Flavoprotein Fluorescence — A Novel Clinical Biomarker of Retinal Metabolic Stress,” which will discuss how retinal metabolic stress is fundamental in the pathogenesis of diabetic retinopathy (DR) and sickle cell retinopathy (SCR), how early detection of elevated oxidative stress may help trigger pre-emptive interventions in chronic conditions or confirm pre-structural response to treatment and how researchers explored the use of flavoprotein fluorescence (FPF) measurement to detect preclinical retinal ischemia in SCR and early response to anti-VEGF therapy in diabetic macular edema (DME) prior to OCT structural changes.

Reference:

1. Mount Sinai Ophthalmologists Present New Research at The Retinal Society Annual Meeting. Mount Sinai Press Office. October 3, 2023. Accessed October 11, 2023.